drugset / Trial / NCT06081595
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
NaSingle-groupOpen-labelTreatment
Summary
This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .
Timeline
- Start
- 2023-10-30
- Primary completion
- 2024-12-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | 100 mg | — |
| Subject | Rivoceranib | Small molecule | 375 mg | — |
Indications
No indication recorded.